Over the forecast period, the global market for alopecia therapy is anticipated to rise due to the rising prevalence of alopecia areata. For instance, the National Institute for Health and Care Excellence (NICE), U.K., estimated that in 2020, there were 15 cases of alopecia per 10,000 people in the U.K. Although it is known to afflict persons of all ages, childhood and adolescence are when it most frequently occurs. There was a peak in occurrence between the ages of 15 and 29. 50–60% of males have their first bald spot before the age of 21. Over the forecast period, it is anticipated that there will be an increase in the number of clinical studies for the treatment of alopecia.
The global Alopecia Treatment Market is estimated to be valued at US$ 8,716.1 Mn in 2021, and is expected to exhibit a CAGR of 5.3% over the forecast period (2021-2028).
Key Competitors in the Alopecia Treatment Industry:
1. Fagron
Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients in Belgium and internationally. Fagron NV was founded in 1990 and is based in Nazareth, Belgium. In September, 2022 Fagron, the leading global player in pharmaceutical compounding, launches DiluCap, a new line of six excipients for compounding pharmacies allowing for easier and faster capsule formulation. It is operational in more than 35 countries worldwide.
2. Cipla Limited
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company was incorporated in 1935 and is headquartered in Mumbai, India. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir.
3. Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and others segments. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. On Feb 2021, Dr. Reddy’s Laboratories has introduced an orally disintegrating formulation of lansoprazole to the U.S. market. Lansoprazole is a proton pump inhibitor, a mechanism of action designed to reduce the amount of acid made in the stomach and thereby treat conditions including indigestion, heartburn, acid reflux and gastroesophageal reflux disease.